




Guide to **Instant ECG** assessment

A flexible program designed to meet the needs of you and your patients' treatment plans.



KardiaMobile® 6L—a fast and simple ECG monitoring device

- ✓ The **first and only FDA-cleared**, clinically validated, handheld 6-lead ECG device^{1,2}
- ✓ Connects via Bluetooth to any **iOS or Android device**
- ✓ Self-administered and simple to use **in office or at home***
- ✓ No disrobing, and no messy gels or wires
- ✓ Actual ECG reading **takes 30 seconds** and is delivered right in the KardiaStation Professional app or faxed within 1 hour of reading in the Direct-to-Patient option
- ✓ **Board-certified cardiologist** overread available for every ECG








Android is a trademark of Google LLC. iOS is a trademark of Cisco.

*Following first reading in office.



ECG Device In-Office Program

ECG Device program for in-office or at-home use

-  ✓ Sign Business Associate Agreement (BAA)[†]/Attestation or enroll via the online Start Form
-  ✓ Receive an email to activate your account within 24 hours
-  ✓ Use the KardiaStation Professional app to record ECG with the KardiaMobile[®] 6L
-  ✓ Use the app or KardiaPro web-based portal to instantly access QTcF results
 - Optional board-certified cardiologist overread available upon request
-  ✓ Once a baseline reading has been done in the office, you may enroll your patients in the at-home ECG program, allowing them to perform subsequent ECG readings from home
-  ✓ For at-home readings, patients must use the Kardia app
-  ✓ Track a patient's complete QTcF results history[‡] in the KardiaPro portal, with the option to download a PDF report to attach to the patient record

Receipt of program equipment is subject to reporting obligations under the Physician Payments Sunshine Act or similar state or federal laws.

ECG=electrocardiogram; QTcF=QT interval corrected by Fridericia's formula.







[†]BAA is with IQVIA; IQVIA administers the ECG Device Program on behalf of Novartis.

[‡]Any QT analysis requested outside of business hours will be reported within 1 hour on the next business day.



ECG Device Direct-to-Patient Program

Patients can complete their ECG without a trip to the office

-  ✓ Sign Business Associate Agreement (BAA)[†]/Attestation or enroll via the online Start Form
-  ✓ Fax the In-Home ECG Testing Device Request form to IQVIA at 833-781-7799
-  ✓ Patient's device will ship within 1 business day via 2-day shipping
 - Patients will also receive a quick start guide and welcome call from their ECG support team to help them set up the device and run their first ECG
-  ✓ QTcF results will be faxed to your office within 1 hour
 - All ECGs will be overread by a board-certified cardiologist
 - Results available by fax only. Email available upon request
-  ✓ Inform the patient of dates they should conduct their remaining ECGs
-  ✓ The patient's device will be deactivated 90 days after the patient receives the device
 - Activation extension available upon request

Sunshine reporting costs are not associated with the direct-to-patient program provided the HCP is not in possession of a KardiaMobile[®] 6L device or portal access.



Download the KardiaStation Professional app for in-office assessment and instant QTcF results via iOS or Android device[§]



Scan with your **iOS** mobile device to download.



Scan with your **Android** mobile device to download.



Instant readings, accurate QTcF results— the **AliveCor KardiaMobile® 6L ECG device**

For in-office or at-home use

For additional information, contact your dedicated Novartis Contact.

For technical support, contact IQVIA at

1-844-324-7823 or email: mdx-ecgsupport@iqvia.com

[§]The equipment or services are not permitted to be used for any purpose outside of the scope of the program. You must not bill any entity or person for any equipment or services relating to the provision or interpretation of the ECG. KardiaMobile 6L, in combination with KardiaStation and/or KardiaPro, can be used by health care professionals to monitor for QT prolongation in patients receiving QT-prolonging medications when access to an ECG machine is not available.

References: 1. FDA grants first ever clearance for six-lead personal ECG device. AliveCor website. May 2019. Accessed March 15, 2024. https://www.alivecor.com/press/press_release/fda-grants-first-ever-clearance-for-six-lead-personal-ecg-device **2.** AliveCor clinical research and other supporting literature. AliveCor website. Updated September 2020. Accessed March 15, 2024. <https://clinicians.alivecor.com/research>